Literature DB >> 23524377

Rodent models of amyotrophic lateral sclerosis.

Philip McGoldrick1, Peter I Joyce, Elizabeth M C Fisher, Linda Greensmith.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterised by the degeneration of upper and lower motor neurons. Recent advances in our understanding of some of the genetic causes of ALS, such as mutations in SOD1, TARDBP, FUS and VCP have led to the generation of rodent models of the disease, as a strategy to help our understanding of the pathophysiology of ALS and to assist in the development of therapeutic strategies. This review provides detailed descriptions of TDP-43, FUS and VCP models of ALS, and summarises potential therapeutics which have been recently trialled in rodent models of the disease. This article is part of a Special Issue entitled: Animal Models of Disease.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23524377     DOI: 10.1016/j.bbadis.2013.03.012

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  66 in total

Review 1.  FTD and ALS--translating mouse studies into clinical trials.

Authors:  Lars M Ittner; Glenda M Halliday; Jillian J Kril; Jürgen Götz; John R Hodges; Matthew C Kiernan
Journal:  Nat Rev Neurol       Date:  2015-05-05       Impact factor: 42.937

2.  Impaired bone homeostasis in amyotrophic lateral sclerosis mice with muscle atrophy.

Authors:  Ke Zhu; Jianxun Yi; Yajuan Xiao; Yumei Lai; Pingping Song; Wei Zheng; Hongli Jiao; Jie Fan; Chuanyue Wu; Di Chen; Jingsong Zhou; Guozhi Xiao
Journal:  J Biol Chem       Date:  2015-02-03       Impact factor: 5.157

3.  Induction of heat shock proteins in differentiated human neuronal cells following co-application of celastrol and arimoclomol.

Authors:  Catherine A S Deane; Ian R Brown
Journal:  Cell Stress Chaperones       Date:  2016-06-08       Impact factor: 3.667

4.  In vivo introduction of transgenes into mouse sciatic nerve cells in situ using viral vectors.

Authors:  Sergio Gonzalez; Ruani N Fernando; Claire Perrin-Tricaud; Nicolas Tricaud
Journal:  Nat Protoc       Date:  2014-04-24       Impact factor: 13.491

Review 5.  Use of biomarkers in ALS drug development and clinical trials.

Authors:  Nadine Bakkar; Ashley Boehringer; Robert Bowser
Journal:  Brain Res       Date:  2014-10-24       Impact factor: 3.252

6.  ROS-related mitochondrial dysfunction in skeletal muscle of an ALS mouse model during the disease progression.

Authors:  Yajuan Xiao; Chehade Karam; Jianxun Yi; Lin Zhang; Xuejun Li; Dosuk Yoon; Huan Wang; Kamal Dhakal; Paul Ramlow; Tian Yu; Zhaohui Mo; Jianjie Ma; Jingsong Zhou
Journal:  Pharmacol Res       Date:  2018-09-18       Impact factor: 7.658

Review 7.  Induced pluripotent stem cells from ALS patients for disease modeling.

Authors:  Jean-Philippe Richard; Nicholas J Maragakis
Journal:  Brain Res       Date:  2014-09-16       Impact factor: 3.252

8.  Increased ROS Level in Spinal Cord of Wobbler Mice due to Nmnat2 Downregulation.

Authors:  Pascal Röderer; Lara Klatt; Felix John; Verena Theis; Konstanze F Winklhofer; Carsten Theiss; Veronika Matschke
Journal:  Mol Neurobiol       Date:  2018-03-16       Impact factor: 5.590

Review 9.  High content analysis in amyotrophic lateral sclerosis.

Authors:  Federica Rinaldi; Dario Motti; Laura Ferraiuolo; Brian K Kaspar
Journal:  Mol Cell Neurosci       Date:  2016-12-11       Impact factor: 4.314

10.  Combined Metabolomics and Transcriptomics Approaches to Assess the IL-6 Blockade as a Therapeutic of ALS: Deleterious Alteration of Lipid Metabolism.

Authors:  Franck Patin; Thomas Baranek; Patrick Vourc'h; Lydie Nadal-Desbarats; Jean-François Goossens; Sylviane Marouillat; Anne-Frédérique Dessein; Amandine Descat; Blandine Madji Hounoum; Clément Bruno; Hervé Watier; Mustafa Si-Tahar; Samuel Leman; Jean-Claude Lecron; Christian R Andres; Philippe Corcia; Hélène Blasco
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.